Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 27, 2023 08:45 ET | Source: Femasys, Inc.

Femasys Announces Notice of Allowance for New U.S. Patent Application Covering Use of FemBloc for Female Permanent Birth Control

ATLANTA, July 27, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting women’s unmet needs worldwide by developing a suite of product candidates and products...
December 19, 2022 09:00 ET | Source: Femasys, Inc.

Femasys Inc. Announces Commercial Availability of its FemCath Intrauterine Device

-- FemCath™ is the first FDA-cleared intrauterine catheter that allows for selective evaluation of a fallopian tube with contrast -- -- FemCath is used in conjunction with FemVue as a baseline...
December 12, 2022 08:30 ET | Source: Femasys, Inc.

Femasys Inc. Reports Encouraging Promotional Launch of FemCerv at AAGL Based on Positive Reception by Gynecologic Physicians and Surgeons

--FemCerv®, the first endocervical tissue sampler of its kind in the detection of cervical cancer, was well-received after being presented at the AAGL conference attended by over 2,000 leading...
November 29, 2022 07:00 ET | Source: Femasys, Inc.

Femasys Inc. Announces Enrollment is over 25% Complete for FemaSeed® De Novo Trial Following Updated Strategic Study Design

ATLANTA, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally...
November 21, 2022 08:30 ET | Source: Femasys, Inc.

Femasys Inc. to Present at the Piper Sandler 34th Annual Healthcare Conference

ATLANTA, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally...
October 20, 2022 08:00 ET | Source: Femasys, Inc.

Femasys Inc. Provides Strategic Update on its FemaSeed® Pivotal Trial Design to Expedite Clinical Program Advancement

- Updated FemaSeed® LOCAL artificial insemination trial design focuses on male factor infertility in patient trial recruitment, with a goal of achieving accelerated enrollment - ATLANTA, Oct. 20,...
October 14, 2022 16:05 ET | Source: Femasys, Inc.

Femasys to Participate in 78th Annual American Society for Reproductive Medicine (ASRM) Scientific Congress

ATLANTA, Oct. 14, 2022 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women’s needs worldwide by developing a suite of product candidates that include minimally...
October 12, 2022 08:00 ET | Source: Femasys, Inc.

Femasys Inc. Announces the Appointment of Christine Thomas as Senior Vice President of Regulatory and Clinical Affairs

ATLANTA, Oct. 12, 2022 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women’s needs worldwide by developing a suite of product candidates that include minimally...